Developer docs
API playgroundTry for free, no card

Search company profiles

Muna Therapeutics

Full company profile

uuid0000out

Namestring
Muna Therapeutics
Legal namestring
Muna Therapeutics ApS
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Muna Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Copenhagen, Denmark (with a US presence in Boston), developing orally administered small-molecule therapeutics for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis. The company's strategy centres on enhancing brain resilience mechanisms — specifically by reprogramming disease-associated microglia through TREM2 agonism — rather than solely clearing pathology. Its lead asset, MNA-001, is a novel potent, selective, orally bioavailable small-molecule TREM2 agonist with best-in-class potential for early Alzheimer's disease; first subjects were dosed in a Phase 1 single-ascending dose / multiple-ascending dose study in November 2025, with topline data expected late summer 2026. A second program comprises small-molecule Kv1.3 potassium channel blockers targeting neuroinflammation in Parkinson's disease and Multiple Sclerosis (preclinical).

The discovery engine is the proprietary MiND-MAP platform (Microglia in NeuroDegeneration – Multi-Omics Analysis Platform), an all-in-human target identification system using single-cell spatial multi-omics and bioinformatics on unique patient tissue cohorts, validated externally in a June 2026 Nature Medicine publication with collaborators VIB, KU Leuven, and the UK Dementia Research Institute. Scientific founders include Bart De Strooper and Simon Glerup, and the company is led by CEO Rita Balice-Gordon and CSO Niels Plath.

Muna is privately held and pre-revenue from product sales. The business model is pharmaceutical R&D: capital comes from a $73M Series A (July 2021, co-led by Novo Holdings and Sofinnova Partners), non-dilutive grants from the Michael J. Fox Foundation ($4.9M, October 2022) and the Alzheimer's Association ($1M, January 2026), and a strategic licensing partnership with GSK worth up to $172.6M (announced June 2025) for neurodegeneration target identification. Once approvals are obtained, commercial revenues are expected to flow through traditional pharma channels (specialty pharmacy, hospital purchasing, physician prescribing) targeting neurologists and memory clinics.

Short descriptiontext

Muna Therapeutics is a clinical-stage biotech developing orally bioavailable small-molecule therapeutics that enhance brain resilience to treat Alzheimer's, Parkinson's, and Multiple Sclerosis, with lead asset MNA-001 (TREM2 agonist) in Phase 1 testing and discovery powered by its MiND-MAP multi-omics platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFrederiksberg, Denmark
HQ citystring
Frederiksberg
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, neurodegenerative disease treatment, alzheimer's drug development, parkinson's therapeutics, neuroscience drug discovery
Industry3 codes
PRIMARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurodegenerative Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Sales
TypeOne Time License
Description

Muna Therapeutics is developing small molecule drug candidates for neurodegenerative diseases. The company will generate revenue through the sale of approved therapeutics once clinical trials are successfully completed and regulatory approvals are obtained. The company is in Phase 1 clinical trials for lead asset MNA-001, with topline data expected mid-2026.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Muna Therapeutics is a clinical-stage biotechnology company developing disease-modifying small molecule therapeutics for neurodegenerative diseases. Its lead asset, MNA-001, is an oral TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. Earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. Drug discovery is powered by the proprietary MiND-MAP platform, which uses single-cell spatial multi-omics on patient brain tissue to identify targets linked to brain resilience.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • MNA-001 demonstrated significant reduction in amyloid burden in mouse models of Alzheimer's-like pathology after three months of treatment
+1 more record
Product overview1 text field

Muna Therapeutics is developing a portfolio of disease-modifying small molecule therapeutics for neurodegenerative diseases. The company's lead product is MNA-001, a TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. The company's earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. These programs are supported by the MiND-MAP discovery platform, which uses human tissue samples and multi-omics analyses to identify and validate new therapeutic targets related to brain resilience mechanisms.

Product and service3 records
1MNA-001
CategorySmall molecule therapeutic — TREM2 agonist for Alzheimer's disease
2Kv1.3 Blockers
CategorySmall molecule therapeutic — Kv1.3 channel blockers for Parkinson's disease and Multiple Sclerosis
3MiND-MAP Platform
CategoryTarget discovery and validation platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-30
Description

GSK committed up to $950 million to acquire 35Pharma while also maintaining earlier-stage partnerships including a licensing deal with Muna Therapeutics worth up to $172.6 million as part of GSK's two-speed pipeline strategy combining broad early-stage partnerships with selective downstream acquisitions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated on seminal Nature Medicine publication identifying critical microglial state transitions as key drivers of Alzheimer's disease. VIB is a Belgian life sciences research institute.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated on Nature Medicine study published June 2026 identifying critical transition in microglia that marks a tipping point between amyloid-beta plaque accumulation and tau pathology. KU Leuven is a leading Belgian university.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborating institution on the Nature Medicine study investigating microglial transitions and Alzheimer's disease resilience mechanisms.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage neuroscience biotech developing immune-modulating therapies for neurodegenerative diseases, with a lead TREM2-targeting program. Highly comparable to Muna given shared TREM2 biology focus and microglia-targeted approach in Alzheimer's.

TypeDirect peer
Description

Clinical-stage biotech developing TREM2-targeted therapeutics for rare and common neurodegenerative diseases. One of the most direct comparables given shared TREM2 agonist strategy and Alzheimer's focus.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration, including microglia- and lysosomal-biology-targeted programs. Closely comparable platform-driven CNS biotech.

TypeDirect peer
Description

Clinical-stage biotech developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a CNS-focused drug developer targeting protein-misfolding and neuroinflammation pathways.

TypeBroad incumbent
Description

Clinical-stage neuroscience company developing small molecule therapies for CNS disorders (acquired by AbbVie). Comparable in modality (small molecule) and CNS focus, with broader indication coverage.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Comparable in modality, stage, and target indication focus.

7Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotech developing small molecule therapies for Alzheimer's disease. Comparable as a small-molecule Alzheimer's developer, though with a different mechanistic approach.

TypeBroad incumbent
Description

CNS-focused clinical-stage biotech (now Biogen partner) developing small molecule therapeutics for neurological disorders. Comparable in CNS small molecule focus and clinical stage.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Comparable in small molecule modality and CNS indication focus.

TypeEmerging player
Description

Clinical-stage biotech developing precision therapeutics for ALS and other neurodegenerative diseases, with shared investor Droia Ventures. Comparable as an emerging CNS biotech with shared European biotech ecosystem and pipeline-driven approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Muna Therapeutics

Neurodegenerative Disease Therapeuticsmunatherapeutics.com

Muna Therapeutics is a clinical-stage biotech developing orally bioavailable small-molecule therapeutics that enhance brain resilience to treat Alzheimer's, Parkinson's, and Multiple Sclerosis, with lead asset MNA-001 (TREM2 agonist) in Phase 1 testing and discovery powered by its MiND-MAP multi-omics platform.

What Muna Therapeutics does

Muna Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Copenhagen, Denmark (with a US presence in Boston), developing orally administered small-molecule therapeutics for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis. The company's strategy centres on enhancing brain resilience mechanisms — specifically by reprogramming disease-associated microglia through TREM2 agonism — rather than solely clearing pathology. Its lead asset, MNA-001, is a novel potent, selective, orally bioavailable small-molecule TREM2 agonist with best-in-class potential for early Alzheimer's disease; first subjects were dosed in a Phase 1 single-ascending dose / multiple-ascending dose study in November 2025, with topline data expected late summer 2026. A second program comprises small-molecule Kv1.3 potassium channel blockers targeting neuroinflammation in Parkinson's disease and Multiple Sclerosis (preclinical).

The discovery engine is the proprietary MiND-MAP platform (Microglia in NeuroDegeneration – Multi-Omics Analysis Platform), an all-in-human target identification system using single-cell spatial multi-omics and bioinformatics on unique patient tissue cohorts, validated externally in a June 2026 Nature Medicine publication with collaborators VIB, KU Leuven, and the UK Dementia Research Institute. Scientific founders include Bart De Strooper and Simon Glerup, and the company is led by CEO Rita Balice-Gordon and CSO Niels Plath.

Muna is privately held and pre-revenue from product sales. The business model is pharmaceutical R&D: capital comes from a $73M Series A (July 2021, co-led by Novo Holdings and Sofinnova Partners), non-dilutive grants from the Michael J. Fox Foundation ($4.9M, October 2022) and the Alzheimer's Association ($1M, January 2026), and a strategic licensing partnership with GSK worth up to $172.6M (announced June 2025) for neurodegeneration target identification. Once approvals are obtained, commercial revenues are expected to flow through traditional pharma channels (specialty pharmacy, hospital purchasing, physician prescribing) targeting neurologists and memory clinics.

Muna Therapeutics firmographics

Firmographics
Name
Muna Therapeutics
Legal name
Muna Therapeutics ApS
Website
https://munatherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Muna Therapeutics is a clinical-stage biotech developing orally bioavailable small-molecule therapeutics that enhance brain resilience to treat Alzheimer's, Parkinson's, and Multiple Sclerosis, with lead asset MNA-001 (TREM2 agonist) in Phase 1 testing and discovery powered by its MiND-MAP multi-omics platform.
Ownership category
akta.pro rank

Muna Therapeutics industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small molecule therapeutics
  • Neurodegenerative disease treatment
  • Alzheimer's drug development
  • Parkinson's therapeutics
  • Neuroscience drug discovery

Where Muna Therapeutics is headquartered

Location

Headquarters

HQ city
Frederiksberg
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Muna Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Sales: Muna Therapeutics is developing small molecule drug candidates for neurodegenerative diseases. The company will generate revenue through the sale of approved therapeutics once clinical trials are successfully completed and regulatory approvals are obtained. The company is in Phase 1 clinical trials for lead asset MNA-001, with topline data expected mid-2026.

Go-to-market motion1 record

Marketing channels5 records

Muna Therapeutics product offering

Product offering

Core offering

Muna Therapeutics is a clinical-stage biotechnology company developing disease-modifying small molecule therapeutics for neurodegenerative diseases. Its lead asset, MNA-001, is an oral TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. Earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. Drug discovery is powered by the proprietary MiND-MAP platform, which uses single-cell spatial multi-omics on patient brain tissue to identify targets linked to brain resilience.

Product overview

Muna Therapeutics is developing a portfolio of disease-modifying small molecule therapeutics for neurodegenerative diseases. The company's lead product is MNA-001, a TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. The company's earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. These programs are supported by the MiND-MAP discovery platform, which uses human tissue samples and multi-omics analyses to identify and validate new therapeutic targets related to brain resilience mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

  • MNA-001
  • Kv1.3 Blockers
  • MiND-MAP Platform

Quantifiable outcome

  • MNA-001 demonstrated significant reduction in amyloid burden in mouse models of Alzheimer's-like pathology after three months of treatment
  • +1 more outcomes

Companies that use Muna Therapeutics

Customer profile

Segments1 record

Ideal customer profiles3 records

Muna Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Muna Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • GSKcoreStrategic or Co-development Partner · 30 June 2025GSK committed up to $950 million to acquire 35Pharma while also maintaining earlier-stage partnerships including a licensing deal with Muna Therapeutics worth up to $172.6 million as part of GSK's two-speed pipeline strategy combining broad early-stage partnerships with selective downstream acquisitions.
  • VIB (Vlaams Instituut voor Biotechnologie)coreStrategic or Co-development PartnerCollaborated on seminal Nature Medicine publication identifying critical microglial state transitions as key drivers of Alzheimer's disease. VIB is a Belgian life sciences research institute.
  • KU LeuvencoreStrategic or Co-development PartnerCollaborated on Nature Medicine study published June 2026 identifying critical transition in microglia that marks a tipping point between amyloid-beta plaque accumulation and tau pathology. KU Leuven is a leading Belgian university.
  • UK Dementia Research Institute (UK-DRI)coreStrategic or Co-development PartnerCollaborating institution on the Nature Medicine study investigating microglial transitions and Alzheimer's disease resilience mechanisms.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Muna Therapeutics competitors and assessment

Company assessment

Direct peers

  • Alector: Clinical-stage neuroscience biotech developing immune-modulating therapies for neurodegenerative diseases, with a lead TREM2-targeting program. Highly comparable to Muna given shared TREM2 biology focus and microglia-targeted approach in Alzheimer's.
  • Vigil Neuroscience: Clinical-stage biotech developing TREM2-targeted therapeutics for rare and common neurodegenerative diseases. One of the most direct comparables given shared TREM2 agonist strategy and Alzheimer's focus.
  • Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration, including microglia- and lysosomal-biology-targeted programs. Closely comparable platform-driven CNS biotech.
  • Prothena: Clinical-stage biotech developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a CNS-focused drug developer targeting protein-misfolding and neuroinflammation pathways.
  • Athira Pharma: Clinical-stage biotech developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Comparable in modality, stage, and target indication focus.
  • Cassava Sciences: Clinical-stage biotech developing small molecule therapies for Alzheimer's disease. Comparable as a small-molecule Alzheimer's developer, though with a different mechanistic approach.
  • Anavex Life Sciences: Clinical-stage biotech developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Comparable in small molecule modality and CNS indication focus.

Broad incumbents

  • Cerevel Therapeutics: Clinical-stage neuroscience company developing small molecule therapies for CNS disorders (acquired by AbbVie). Comparable in modality (small molecule) and CNS focus, with broader indication coverage.
  • Sage Therapeutics: CNS-focused clinical-stage biotech (now Biogen partner) developing small molecule therapeutics for neurological disorders. Comparable in CNS small molecule focus and clinical stage.

Emerging players

  • QurAlis: Clinical-stage biotech developing precision therapeutics for ALS and other neurodegenerative diseases, with shared investor Droia Ventures. Comparable as an emerging CNS biotech with shared European biotech ecosystem and pipeline-driven approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Muna Therapeutics social profiles

Digital presence

Muna Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Muna Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Muna Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Muna Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Muna Therapeutics

What does Muna Therapeutics do?

Muna Therapeutics is a clinical-stage biotechnology company developing disease-modifying small molecule therapeutics for neurodegenerative diseases. Its lead asset, MNA-001, is an oral TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. Earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. Drug discovery is powered by the proprietary MiND-MAP platform, which uses single-cell spatial multi-omics on patient brain tissue to identify targets linked to brain resilience.

Is Muna Therapeutics a public or private company?

Muna Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Muna Therapeutics founded?

Muna Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Muna Therapeutics based?

Muna Therapeutics is headquartered in Frederiksberg, Denmark, in the Europe region.

How does Muna Therapeutics make money?

One revenue line is on record: pharmaceutical Development and Sales.

Who are Muna Therapeutics's main competitors?

Direct peers on record are Alector, Vigil Neuroscience, Denali Therapeutics, Prothena, Athira Pharma, Cassava Sciences and Anavex Life Sciences. Broad incumbents are Cerevel Therapeutics and Sage Therapeutics. QurAlis is listed as an emerging player.

Does Muna Therapeutics have an API?

No public API is recorded for Muna Therapeutics.

What industry is Muna Therapeutics in?

Muna Therapeutics's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyMuna oral pill shifts aging brain markers in trialMuna Therapeutics reported Phase 1 results for its oral TREM2-targeting drug MNA-001, which shifted age-linked brain markers in elderly volunteers toward younger levels. The study found no serious adverse events and the drug reached the central nervous system well. The company plans a Phase 2 study in early 2027 to assess cognitive and disease-progression benefits.Longevity.TechnologyMuna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trialMuna Therapeutics reported positive Phase 1 results for MNA-001, an oral TREM2 modulator, in a randomized, double-blind, placebo-controlled study. No serious adverse events occurred, and dose-dependent reductions in CSF and plasma soluble TREM2 were observed. The company plans to initiate a Phase 2 study in early 2027.PR NewswireMuna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator, MNA-001, in Alzheimer's DiseaseMuna Therapeutics announced positive Phase 1 results for MNA-001, an oral TREM2 modulator, in Alzheimer's disease. The study showed favorable safety, strong CSF exposure, and dose-dependent target engagement, with age-associated brain inflammation markers shifting toward younger levels. The company plans to initiate a Phase 2 study in 2027.The Pharma LetterMuna names Michel Detheux CEO as Alzheimer’s drug nears Phase II testingDanish biotech company Muna Therapeutics has appointed Michel Detheux as its new chief executive, succeeding founding CEO Rita Balice-Gordon, who will transition to the board. Detheux joins from iTeos Therapeutics (NASDAQ: ITOS) and takes the helm as Muna advances its lead Alzheimer's disease candidate toward Phase II clinical testing.AijournMuna Therapeutics Announces CEO Transition as Clinical Pipeline AdvancesMuna Therapeutics announced a CEO transition from Rita Balice-Gordon, Ph.D., to Michel Detheux, Ph.D., effective June 29, 2026. The company is focused on developing therapies for neurodegenerative diseases, with its lead asset, MNA-001, progressing toward Phase 2 trials in early Alzheimer's patients by early 2027.Stock TitanMuna Therapeutics names Detheux CEOMuna Therapeutics announced a CEO transition, appointing Michel Detheux as CEO effective June 29, 2026, replacing Rita Balice-Gordon who will join the company's Board of Directors. The company focuses on developing therapies for neurodegenerative diseases, with a lead TREM2 agonist on track for Phase 2 testing in early Alzheimer's patients in 2027. The appointment aims to build on the company's progress and strategic partnerships in advancing its neurodegenerative pipeline.PR NewswireMuna Therapeutics Announces CEO Transition as Clinical Pipeline AdvancesMuna Therapeutics announced a CEO transition, with Michel Detheux replacing Rita Balice-Gordon, effective June 29, 2026. The company is advancing its neurodegenerative therapies, with its lead TREM2 agonist preparing for Phase 2 clinical trials in early Alzheimer's in 2027.Technology NetworksWhy Do Some People Avoid Dementia Despite Alzheimer’s Brain Changes?Researchers from VIB, KU Leuven, UK-DRI, and Muna Therapeutics identified critical transitions in microglia—the brain's immune cells—that may determine whether Alzheimer's disease pathology progresses to dementia. The study, published in Nature Medicine, analyzed brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians, and found that resilience can arise through different biological mechanisms depending on age group. The findings suggest that targeting microglial state transitions, particularly pathways such as TREM2, could open new therapeutic avenues to delay or prevent disease progression.